Security Notice: Please be aware of impersonation attempts using our company name
Legitimate communications from Ascent Research will only come from official @ascentresearch.com email addresses.
Quick Order Cart

Cat. No. ARG33738

ACTN4 Knockout jurkat Polyclonal Cells

  • Product Type:

    Polyclonal Cell Population

  • Species:

    Homo sapiens (Human)

  • Tissue Source:

    Blood (peripheral blood)

  • Disease:

    Acute lymphoblastic leukemia (ALL)

ACTN4 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the Jurkat human T lymphocyte line. These cells lack functional alpha-actinin-4, an actin-bundling protein that crosslinks F-actin and regulates integrin-mediated adhesion, migration, and signaling via PI3K/AKT and NF-??B pathways. The model enables investigation of ACTN4 in T cell adhesion, leukemic invasion, and actin remodeling. Key applications include dissecting cancer metastasis mechanisms, validating anti-metastatic drug targets, and analyzing transcriptional regulation by actin-binding proteins using assays such as Western blotting, migration assays, and phospho-signaling analysis.

Inquire Now

In stock

Ships next business day


Ask a Question

Shipping Info:

Cryopreserved in vials and shipped on dry ice


Disclaimer:

For Research Use Only

  • Characteristics

    Host Cell

    Jurkat

    Cell Type

    T cell line

    Sex of Donor

    Male

    Age

    14 years

    Derived From Site

    In situ; Peripheral blood

    Gene Name

    ACTN4

    Gene Identifier

    NCBI Gene ID 81

    Growth Mode

    Suspension

    Storage

    Liquid nitrogen (LN2)

  • Culture Conditions

    Growth medium

    RPMI 1640

    Supplement(s)

    10% Fetal Bovine Serum, 1% Penicillin-Streptomycin Solution

    Temperature

    37°C

    Atmosphere

    5% CO₂

  • Quality Control

    Sterility testing

    The bacterial, yeast, and fungi are not detected in these cells by daily monitor.

    Mycoplasma testing

    Negative for mycoplasma through PCR analysis

  • Disclaimer

    Intended Use

    This product is intended for laboratory in vitro use only. lt is not intended for diagnostic, therapeutic, or clinical applications.

    Disclaimer

    Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability. References to scientific literature and patents are for informational purposes only, and the customer assumes sole responsibility for verifying their accuracy.

    By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use, including compliance with all applicable safety and environmental regulations and precautions. Relevant laws, regulations, and ethical guidelines must be followed in conducting any research, modifications, or derivatives derived from this product.

    This product is provided "AS IS", and except as expressly stated herein, Ascent Research disclaims all other warranties, express or implied. Under no circumstances shall Ascent Research, its affiliates, or representatives be liable for indirect, incidental, consequential, or punitive damages arising from the use of this material. While Ascent Research employs rigorous quality control measures, we shall not be held responsible for damages resulting from misidentification or misinterpretation of the provided materials.

Description

ACTN4 Knockout Jurkat Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal population with targeted disruption of the ACTN4 gene in the Jurkat T lymphocyte line. This heterogeneous knockout pool eliminates functional alpha-actinin-4 protein, enabling population-level studies of loss-of-function phenotypes without clonal selection. The model is designed for investigating actin cytoskeleton regulation, adhesion dynamics, and associated signaling pathways in a leukemic T cell context.

The Jurkat host cell line originates from a 14-year-old male with acute T cell leukemia and is widely used to study T cell receptor signaling, cytokine production, and apoptosis. Its leukemic background and constitutively active proximal TCR signaling components make it an ideal background for examining oncogenic and immunological pathways relevant to T-cell acute lymphoblastic leukemia. Jurkat cells respond robustly to stimuli such as phorbol myristate acetate and ionomycin, facilitating diverse functional assays.

Alpha-actinin-4 is an actin-bundling protein that crosslinks F-actin filaments and scaffolds focal adhesion complexes by interacting with vinculin, zyxin, and integrin ??1 (CD29). ACTN4 is regulated by upstream factors including PI3K, AKT, TGF-??, RAC1, and SRC kinases, and it mediates downstream effects such as F-actin stabilization, MMP-9 upregulation, and NF-??B activation via p65 (RELA). Loss of ACTN4 disrupts actin architectures and uncouples mechanical inputs from signal transduction through FAK, RhoA, and IKK, thereby affecting transcriptional programs driven by Snail and E-cadherin.

In T cells, ACTN4 supports integrin-mediated adhesion and polarized migration essential for immune surveillance and leukemic dissemination. ACTN4 knockout Jurkat cells show impaired actin remodeling, reduced adhesion to extracellular matrix, and attenuated transendothelial migration. This model is particularly valuable for probing invasion mechanisms in T-cell acute lymphoblastic leukemia, as ACTN4-dependent NF-??B signaling and MMP-9 secretion promote tissue infiltration. Additionally, diminished PI3K/AKT activity in these knockout cells may alter survival and proliferation, offering a tool for testing inhibitors of adhesion-dependent leukemia progression.

Applications include Western blotting and RT-qPCR for knockout validation, immunofluorescence and phalloidin staining to detect F-actin disorganization, and Transwell migration/invasion assays to quantify motility defects. Phospho-specific analysis of AKT and p65, co-immunoprecipitation of ACTN4-interacting proteins, and reporter assays (NF-??B, AP-1) facilitate mechanistic dissection. The polyclonal population is suitable for drug target validation in anti-metastatic research and for studying transcriptional coregulation by actin-binding proteins. For further information, please contact Ascent Research.

Reset Password

    Reach Us Questions? Click Me Here!

    Fill out the form below and a member of our team will contact you shortly!

    *Required field



      Reach Us

      Fill out the form below and a member of our team will contact you shortly!

      *Required field

      Product Inquiry (Optional)